Chen W, Brown S, Gazzard B, Howard L; International Conference on AIDS.
Int Conf AIDS. 1990 Jun 20-23; 6: 170 (abstract no. Th.B.211).
Westminster Hospital, London, UK
OBJECTIVE: To evaluate the effect of Megace on body weight in HIV patients with or without gastrointestinal disturbance. METHOD: Twenty-five patients, who had lost more than 5% body weight, given Megace (40-169mg) were weighted and reviewed 3 months prior to treatment and monthly thereafter. RESULT: 3 patterns of weight change were observed: A, consistent weight-gain over 4 months (more than 5% of pre-treatment body weight); B, transient weight-gain followed or preceded by weight-loss; and C, no weight gain or continuing weight-loss. Patients with gastrointestinal symptoms (diarrhoea, oesophagitis or severe abdominal pain) were seen in only 1 out of 8 in group A (this patient had giardiasis and responded to Metronidazole); 8 of 10 (80%) in group B; and 5 of 7 (72%) in group C. Treatment of the underlying gastrointestinal disease produced significant weight gain (more than 5% body weight) in 3 patients. Patients with visceral Kaposi's sarcoma (2) or MAI infection (2) were only seen in group C. CONCLUSION: Megace can produce consistent weight gain in patients without gastrointestinal disease, visceral Kaposi's sarcoma or atypical mycobacterium infection. Successful treatment of underlying gastrointestinal disease also produces weight gain in patients who had previously not responded to Megace.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Antiretroviral Therapy, Highly Active
- Body Weight
- Diet, Reducing
- HIV Infections
- HIV Seropositivity
- Humans
- Nutritional Status
- Retrospective Studies
- Weight Gain
- Weight Loss
- drug therapy
- therapy
Other ID:
UI: 102181762
From Meeting Abstracts